These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11147583)

  • 1. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
    Chang J; Ormerod M; Powles TJ; Allred DC; Ashley SE; Dowsett M
    Cancer; 2000 Dec; 89(11):2145-52. PubMed ID: 11147583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.
    Koda M; Sulkowska M; Kanczuga-Koda L; Tomaszewski J; Kucharczuk W; Lesniewicz T; Cymek S; Sulkowski S
    Oncol Rep; 2007 Jul; 18(1):113-9. PubMed ID: 17549355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
    Parton M; Krajewski S; Smith I; Krajewska M; Archer C; Naito M; Ahern R; Reed J; Dowsett M
    Clin Cancer Res; 2002 Jul; 8(7):2100-8. PubMed ID: 12114409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between Ki-67 index and S-phase fraction on fine-needle aspiration samples from breast carcinoma.
    Bozzetti C; Nizzoli R; Camisa R; Guazzi A; Ceci G; Cocconi G; Mazzini G; Naldi N
    Cancer; 1997 Oct; 81(5):287-92. PubMed ID: 9349516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
    Stearns V; Singh B; Tsangaris T; Crawford JG; Novielli A; Ellis MJ; Isaacs C; Pennanen M; Tibery C; Farhad A; Slack R; Hayes DF
    Clin Cancer Res; 2003 Jan; 9(1):124-33. PubMed ID: 12538460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.
    Makris A; Powles TJ; Allred DC; Ashley SE; Trott PA; Ormerod MG; Titley JC; Dowsett M
    Breast Cancer Res Treat; 1999 Jan; 53(1):51-9. PubMed ID: 10206072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer.
    Chakravarthy AB; Kelley MC; McLaren B; Truica CI; Billheimer D; Mayer IA; Grau AM; Johnson DH; Simpson JF; Beauchamp RD; Jones C; Pietenpol JA
    Clin Cancer Res; 2006 Mar; 12(5):1570-6. PubMed ID: 16533783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
    Vincent-Salomon A; Rousseau A; Jouve M; Beuzeboc P; Sigal-Zafrani B; Fréneaux P; Rosty C; Nos C; Campana F; Klijanienko J; Al Ghuzlan A; Sastre-Garau X;
    Eur J Cancer; 2004 Jul; 40(10):1502-8. PubMed ID: 15196533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
    Krajewski S; Blomqvist C; Franssila K; Krajewska M; Wasenius VM; Niskanen E; Nordling S; Reed JC
    Cancer Res; 1995 Oct; 55(19):4471-8. PubMed ID: 7671262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.